zika
viru
zikv
arthropodborn
viru
arboviru
belong
famili
flavivirida
genu
flaviviru
singlestrand
posit
rna
viru
genom
zikv
approxim
kb
encod
three
structur
protein
seven
nonstructur
protein
wang
et
al
zikv
discov
isol
sentinel
rhesu
monkey
zika
forest
uganda
dick
et
al
howev
first
outbreak
zikvcaus
diseas
report
brazil
petersen
et
al
one
million
case
sinc
rapidli
spread
countri
around
world
particularli
south
america
render
zikv
public
health
threat
han
mespled
figur
mild
symptom
includ
fever
rash
headach
joint
pain
major
concern
involv
potenti
sever
neurolog
disord
microcephali
neurolog
disord
newborn
meningoenceph
syndrom
myeliti
ocular
abnorm
barro
et
al
neither
specif
antivir
drug
vaccin
develop
prevent
cure
zikv
infect
howev
sever
wellcharacter
drug
target
encod
viru
present
host
cell
may
help
us
prevent
treat
zikv
infect
review
focu
current
progress
research
develop
smallmolecul
zikv
inhibitor
either
viral
host
cell
inhibitor
target
differ
stage
zikv
life
cycl
data
essenti
design
drug
drug
deliveri
modal
zikv
relat
virus
life
cycl
zikv
divid
four
stage
includ
viru
entri
genom
replic
viru
assembl
releas
matur
zikv
particl
first
adher
host
cell
interact
specif
receptor
host
cell
dcsign
axl
tyro
musso
gubler
nowakowski
et
al
meerten
et
al
sever
protein
includ
dcsign
tim
well
tam
protein
belong
phosphatidylserin
receptor
famili
report
act
receptor
entri
dengu
viru
denv
lozach
et
al
meerten
et
al
pereralecoin
et
al
determin
whether
receptor
also
involv
zikv
entri
seri
transfect
cell
express
dcsign
tam
famili
member
axl
could
infect
zikv
vari
degre
hamel
et
al
dcsign
consist
group
ii
calciumdepend
singl
carbohydr
recognit
domain
transmembran
ctype
lectin
interact
carbohydr
recognit
domain
bind
carbohydr
viral
protein
e
zelenski
greadi
cruzoliveira
et
al
dcsign
also
play
import
role
flaviviru
bind
infect
myeloid
cell
navarrosanchez
et
al
mediat
attach
viral
particl
cell
surfac
facilit
interact
primari
receptor
host
cell
chen
et
al
germi
et
al
axl
belong
tam
famili
group
three
receptor
protein
tryrosin
kinas
mediat
clearanc
apoptot
cell
lemk
rothlin
axl
express
astrocyt
microglia
human
brain
develop
mediat
zikv
infect
glial
cell
nowakowski
et
al
meerten
et
al
axl
consist
two
differ
epitop
includ
ntermin
iglik
domain
second
ig
domain
exist
dimer
form
ligand
axl
connect
zikv
glial
cell
abund
cell
mucos
epitheli
cell
mast
cell
mediat
attach
zikv
particl
cell
surfac
facilit
interact
axl
well
subsequ
infect
hamel
et
al
avail
differ
entri
receptor
like
provid
evolutionari
advantag
viru
result
viru
abl
infect
wide
rang
human
host
cell
bind
host
cell
zikv
intern
clathrinmedi
endocytosi
traffic
endosom
wang
x
et
al
mottin
et
al
process
enter
host
cell
axl
kinas
activ
activ
complex
downregul
interferon
signal
promot
infect
endosom
membran
viru
envelop
e
fuse
acid
environ
endosom
viral
genom
rna
releas
cytoplasm
wang
x
et
al
mottin
et
al
process
viru
entri
inhibitor
block
viral
attach
endocytosi
fusion
protein
e
zikv
dcsign
axl
tyro
entryadhes
factor
host
cell
involv
viral
attach
endocytosi
fusion
entri
hasan
et
al
heinz
stiasni
shi
gao
therefor
serv
target
develop
small
molecul
inhibitor
viru
entri
genom
zikv
translat
cleav
three
structur
protein
includ
capsid
c
precursor
membran
protein
prm
membran
protein
envelop
e
well
seven
nonstructur
protein
protein
relat
flaviviru
replic
virion
matur
protein
activ
activ
region
protein
form
complex
protein
exert
proteolyt
enzym
activ
protein
compris
endoplasm
reticulum
er
associ
replic
complex
protein
contain
ctermin
rnadepend
rna
polymeras
domain
ntermin
methyltransferas
domain
cooper
initi
extens
rna
synthesi
addit
protein
largest
ns
protein
molecular
weight
highli
conserv
rna
replic
action
proteinas
helicas
methyltransferas
virus
encod
essenti
proteas
viral
replic
process
serv
target
therapeut
intervent
methyl
ssrna
c
e
prm
protein
assembl
form
immatur
virion
er
er
vesicl
transport
viru
particl
golgi
apparatu
viru
particl
undergo
surfac
polysaccharid
modif
prme
protein
trimer
rearrang
furin
proteas
cleavag
prm
matur
viru
particl
smooth
surfac
produc
final
leav
host
cell
exocytosi
matur
viru
figur
wang
x
et
al
mottin
et
al
small
molecul
inhibitor
target
c
protein
inhibit
viral
capsid
format
abl
affect
viral
assembl
releas
meanwhil
correct
express
process
nascent
protein
host
cell
essenti
effici
viral
replic
sever
host
protein
er
membran
complex
cyclophilin
proteasom
element
respons
monitor
proper
protein
synthesi
fold
degrad
impair
function
result
reduc
viral
assembl
bud
therefor
host
protein
may
also
serv
target
develop
small
molecul
zikv
inhibitor
antivir
drug
smallmolecul
inhibitor
target
differ
stage
viral
life
cycl
interact
viru
host
protein
critic
viru
replic
de
clercq
li
exampl
inhibit
axl
function
protect
cell
infect
thu
may
potenti
target
product
entri
inhibitor
howev
destroy
axl
function
may
also
mani
advers
consequ
nowakowski
et
al
addit
proteas
crucial
zikv
replic
potenti
target
develop
zikv
replic
inhibitor
therefor
effect
appropri
target
need
develop
research
structur
zikv
envelop
protein
e
protein
similar
flavivirus
three
characterist
domain
central
domain
slender
fingerlik
domain
ii
ctermin
immunoglobulinlik
domain
iii
dai
et
al
recognit
bind
zikv
e
protein
host
cell
receptor
mark
begin
zikv
infect
therefor
inhibitor
design
envelop
protein
effect
inhibit
viru
infect
byrd
et
al
small
molecul
inhibitor
specif
target
zikv
e
protein
report
peptid
tabl
deriv
stem
region
zikv
e
protein
inhibit
vertic
transmiss
zikv
pregnant
mice
protect
type
type
iii
interferon
receptordefici
mice
lethal
zikv
challeng
yu
et
al
peptid
interact
viral
e
protein
form
membran
pore
disrupt
integr
viral
membran
yu
et
al
figur
fernando
et
al
bind
zikv
e
protein
preferenti
compar
glycan
block
format
glycosid
bond
zikv
host
vero
cell
concentr
tabl
fernando
et
al
small
molecul
inhibitor
nonspecif
target
zikv
e
protein
also
activ
medic
relev
virus
use
similar
rout
entri
peptid
extract
stem
japanes
enceph
viru
e
protein
inhibit
zikv
entri
host
cell
chang
conform
e
protein
low
ph
hydrophob
last
seven
amino
acid
residu
also
consid
key
bind
viral
membran
tabl
chen
et
al
vivo
experi
mice
highli
sensit
zikv
show
inhibit
spermat
tubul
disord
reproduct
epitheli
cell
degener
also
allevi
circulatori
constrict
blood
vessel
chen
et
al
molecular
tweezer
potent
inhibit
activ
envelop
virus
inhibit
zikv
strain
vero
cell
figur
tabl
destroy
intact
membran
structur
enrich
high
level
sphingolipid
cholesterol
bavari
et
al
chazal
gerlier
brugger
et
al
loriz
et
al
rocker
et
al
addit
inhibit
zikv
infect
semen
urin
saliva
cerebrospin
fluid
bodi
fluid
lose
activ
serum
rocker
et
al
studi
attribut
effect
rel
high
protein
content
serum
rocker
et
al
baicalin
figur
high
affin
viru
e
protein
low
toxic
cell
inhibit
zikv
enter
cell
tabl
oo
et
al
epigallocatechin
gallat
egcg
polyphenol
green
tea
shown
inhibit
mani
virus
figur
tabl
isaac
et
al
nanc
et
al
calland
et
al
accordingli
egcg
bind
zikv
e
protein
block
zikv
entri
host
cell
song
et
al
howev
egcg
contain
catechol
group
may
nonspecif
inhibit
mani
differ
target
mottin
et
al
curcumin
inhibit
zikv
infect
dosedepend
manner
figur
replic
inhibitor
zikv
also
prevent
viral
e
protein
bind
cell
surfac
mounc
et
al
roy
et
al
vero
cell
valu
curcumin
inhibit
zikv
respect
tabl
mounc
et
al
nanchangmycin
figur
produc
streptomyc
nanchang
ferment
inhibit
gramposit
bacteria
insecticid
antibacteri
activ
poultri
vitro
rausch
et
al
zika
viru
nanchangmycin
inhibit
zikv
infect
block
clathrinmedi
endocytosi
low
toxic
rang
tabl
human
cell
human
brain
microvascular
endotheli
cell
hbmec
human
cell
respect
rausch
et
al
endosom
provid
transport
rout
zikv
enter
host
cell
tabl
endosom
scorpion
peptid
inhibitor
effect
inhibit
zikv
infect
noncytotox
concentr
li
et
al
broadspectrum
specif
antivir
peptid
alkal
ph
valu
endosom
inhibit
releas
viral
genom
prevent
enter
cytoplasm
thu
block
zikv
infect
li
et
al
cell
reduc
zikv
infect
concentr
li
et
al
chloroquin
li
et
al
suramin
albulescu
et
al
figur
tabl
li
et
al
demonstr
abil
inhibit
zikv
intern
vitro
niclosamid
fdaapprov
drug
broadli
use
treatment
intestin
helminthiasi
figur
tabl
prevent
endosom
acidif
mechan
fulli
elucid
fonseca
et
al
jurgeit
et
al
axl
tyrosin
kinas
receptor
tkr
mediat
viral
attach
host
cell
therefor
necessari
inhibit
primari
cell
high
axl
content
nowakowski
et
al
cabozantinib
two
kinas
inhibitor
inhibit
axl
figur
rausch
et
al
human
cell
valu
respect
valu
greater
tabl
rausch
et
al
howev
experi
show
axl
inhibitor
effect
axlrich
cell
rausch
et
al
indic
effect
celltyp
specif
although
sever
studi
proclaim
axl
receptor
zikv
entri
vitro
report
show
opposit
result
genet
ablat
axl
signific
effect
zikv
entri
zikvmedi
cell
death
humaninduc
pluripot
stem
cell
ipsc
deriv
npc
cerebr
organoid
nybo
andersen
et
al
rausch
et
al
report
cell
show
detect
axl
express
highli
permiss
zikv
infect
suggest
axl
may
essenti
zikv
infect
hypothesi
corrobor
vivo
studi
wang
z
et
al
notabl
axl
receptor
support
neural
stem
cell
surviv
prolifer
neurogenesi
ji
et
al
signal
axl
also
regul
barrier
bbb
integr
context
viral
infect
miner
et
al
therefor
block
axl
may
protect
zikv
infect
viral
replic
perturb
axl
function
may
also
multipl
advers
consequ
therefor
use
axl
receptor
idea
target
inhibit
zika
viru
infect
remain
confirm
effort
elucid
molecular
mechan
zikv
infect
target
tam
receptor
knockout
studi
unbias
screen
bind
factor
render
cell
resist
zikv
lead
identif
new
target
develop
antizikv
therapeut
proteas
zika
viru
play
essenti
role
zikv
replic
matur
process
viral
nonstructur
protein
viral
polyprotein
individu
protein
serin
proteas
consist
ntermin
domain
short
cofactor
hydrophil
core
sequenc
like
cofactor
hcv
proteas
flaviviru
inact
without
cofactor
erbel
et
al
three
differ
zikv
proteas
zikvpro
construct
propos
first
coval
linker
peptid
gzipro
construct
adopt
base
previou
west
nile
denv
proteas
construct
lei
et
al
two
construct
includ
one
bival
proteas
consist
two
separ
polypeptid
bzipro
zhang
et
al
one
ctermin
peptid
tgkr
bind
ezipro
phoo
et
al
remark
singlechain
enzym
gzipro
artifici
linker
commonli
appli
construct
flavivirus
wide
use
screen
inhibitor
aprotinin
amino
acid
bovin
trypsin
inhibitor
inhibit
zikv
proteas
nm
block
interact
predict
molecular
model
studi
tabl
shiryaev
et
al
use
structurebas
virtual
screen
novobiocin
lopinavirritonavir
inhibit
zikv
proteas
activ
use
molecular
dock
analysi
figur
yuan
et
al
novobiocin
aminocoumarin
antibiot
inhibit
proteas
activ
highli
stabl
bind
zikv
proteas
diminish
catalyt
effici
kirbi
et
al
yuan
et
al
inhibit
zikv
replic
vero
cell
cell
tabl
yuan
et
al
lopinavirritonavir
inhibit
proteas
activ
zikv
replic
vero
cell
cell
tabl
yuan
et
al
recent
phoo
et
al
shown
glycinerich
artifici
linker
tgkr
peptid
could
introduc
steric
hindranc
result
chang
inhibitorbind
mechan
phoo
et
al
widetyp
domain
coval
link
kim
et
al
bzipro
closer
nativ
state
higher
activ
suitabl
inhibitor
screen
gzipro
ezipro
free
activ
site
access
substrat
inhibitor
de
la
cruz
et
al
phoo
et
al
shannon
et
al
acylkraldehyd
dipeptid
form
coval
bond
residu
kr
residu
occupi
site
li
et
al
acylkraldehyd
inhibit
bzipro
construct
proteas
nm
tabl
li
et
al
nuclear
magnet
reson
nmr
spectroscopi
demonstr
bzipro
construct
acylkraldehyd
form
stabl
complex
li
et
al
peptidomimet
inhibitor
compos
segment
differ
residu
includ
hydrolysi
product
hydrolysi
product
figur
inhibit
zikv
replic
proteas
zikv
respect
tabl
phoo
et
al
noncompetit
inhibitor
five
macrocycl
peptid
act
ligand
high
affin
rapidli
isol
nearli
target
use
display
screen
approach
mrna
display
phage
display
passioura
et
al
peptid
inhibit
bzipro
construct
proteas
activ
nitsch
et
al
ahd
peptid
amphipath
peptid
protect
lethal
zikv
infect
primari
neuron
cell
inhibit
zikv
infect
mous
brain
preserv
bbb
integr
tabl
cho
et
al
jackman
et
al
ahd
peptid
also
significantli
reduc
viral
load
serum
brain
spleen
optic
nerv
throughout
cours
infect
jackman
et
al
four
dipeptid
inhibitor
ctermin
boron
acid
moieti
includ
bz
pheargb
oh
bz
pheargb
oh
bz
phe
argb
oh
pheargb
oh
figur
compound
inhibit
zikv
proteas
activ
tabl
nitsch
et
al
li
et
al
found
pyrazol
ester
deriv
sulfonyl
benzoat
figur
inhibit
zikv
replic
benzoylnlelysargargaminomethylcoumarin
bznkrramc
use
substrat
tabl
li
et
al
benzoyl
group
inhibitor
form
coval
bond
side
chain
catalyt
residu
stabil
close
conform
zikv
bzipro
construct
proteas
li
et
al
addit
deriv
pyrazol
ester
sulfonyl
benzoat
interact
manner
similar
compound
figur
strongli
inhibit
binari
zikv
bzipro
construct
proteas
li
et
al
hydroxychloroquin
figur
drug
alreadi
approv
use
pregnanc
inhibit
bzipro
construct
proteas
activ
inhibit
constant
ki
tabl
kumar
et
al
natur
product
edibl
plant
like
myricetin
inhibit
zikv
infect
inhibitori
constant
zikv
proteas
activ
ki
establish
six
hydrogen
bond
four
zika
residu
figur
tabl
roy
et
al
apigenin
inhibit
zikv
infect
inhibitori
constant
ki
figur
tabl
roy
et
al
isorhamnetin
also
call
inhibit
zikv
infect
ki
well
quercetin
ki
figur
tabl
roy
et
al
structur
isorhamnetin
deriv
quercetin
similar
molecular
structur
roy
et
al
addit
curcumin
figur
tabl
natur
phenol
two
aromat
ring
link
heptadien
group
inhibit
zikv
infect
ki
like
bival
bind
site
song
ni
roy
et
al
introduct
ctermin
boron
acid
moieti
dipeptid
inhibitor
rais
affin
target
nitsch
et
al
howev
curcumin
quercetin
flavonoid
shown
promiscu
inhibitor
eg
via
colloid
aggreg
mcgovern
et
al
duan
et
al
tritsch
et
al
curcumin
also
contain
reactiv
michael
acceptor
quercetin
catechol
wellknown
pain
substructur
might
make
compound
less
favor
mottin
et
al
total
approv
investig
drug
screen
use
highthroughput
screen
ht
assay
li
et
al
among
compound
confirm
possess
three
includ
temoporfin
niclosamid
nitazoxanid
could
inhibit
cell
respect
figur
tabl
baell
holloway
temoporfin
test
viremia
mous
model
lethal
mous
model
abl
inhibit
viremia
protect
mice
mice
surviv
present
sign
neurolog
disord
li
et
al
compound
inhibit
interact
ntermin
fragment
use
epharmacophorebas
virtual
screen
assay
ba
chosen
potent
zika
protein
inhibitor
figur
howev
experiment
data
inhibitor
shown
tabl
rohini
et
al
berberin
fdaapprov
drug
denv
shown
high
bind
affin
kcalmol
bind
around
activ
site
receptor
figur
tabl
sahoo
et
al
niclosamid
fdaapprov
categori
b
anthelmint
drug
treat
worm
infect
human
domest
livestock
inhibit
three
strain
zikv
measur
intracellular
zikv
rna
level
valu
cell
xu
et
al
investig
compound
function
cyclindepend
kinas
inhibitor
cdki
inhibit
three
stain
valu
measur
intracellular
zikv
rna
level
cell
xu
et
al
accord
experiment
result
mechan
two
compound
occur
postentri
stage
like
viral
rna
replic
step
xu
et
al
suramin
figur
approv
polyanion
antiparasit
drug
potenti
inhibitor
zika
viru
complex
proteinas
tabl
coronado
et
al
comput
analysi
show
suramin
suppress
proteinas
activ
block
catalyt
residu
interact
catalyt
histidin
residu
coronado
et
al
erythrosin
b
figur
pregnanc
categori
b
food
addit
inhibit
zikv
replic
target
proteas
cell
tabl
via
noncompetit
mechan
enzymat
kinet
experi
li
z
et
al
erythrosin
b
also
inhibit
zikv
rna
synthesi
protein
express
zikvrelev
neural
progenitor
human
placent
cell
li
z
et
al
two
inhibitor
test
inhibit
proteas
activ
valu
block
activ
site
zikv
proteas
dock
conform
lee
et
al
five
polyphenol
compound
includ
luteolin
astragalin
rutin
epigallocatechin
gallat
gallocatechin
gallat
flavon
flavonol
inhibit
zikv
replic
valu
rang
figur
tabl
lim
et
al
zika
viru
rel
conserv
larg
protein
among
member
genu
contain
mtase
domain
rna
polymeras
rdrp
domain
connect
residu
linker
zikv
use
templat
genom
replic
effici
similar
rna
templat
lu
et
al
one
studi
zikv
could
extend
rna
primer
anneal
rna
templat
manner
oppos
lu
et
al
interact
interact
virtual
condit
inhibit
zikv
propag
clear
data
report
figur
tabl
ramharack
soliman
baicalein
figur
flavonoid
analog
could
downregul
zikv
replic
h
postinfect
prophylact
effect
evid
pretreat
vero
cell
select
index
si
tabl
oo
et
al
also
antivir
activ
denv
chikungunya
viru
chikv
influenza
viru
zandi
et
al
moghaddam
et
al
jin
et
al
oo
et
al
figur
tabl
pyridoxinederiv
nonnucleosid
smallmolecul
inhibitor
xu
et
al
compound
inhibit
zikv
block
rna
synthesi
reaction
catalyz
recombin
zikv
polymeras
xu
et
al
nuclear
import
inhibitor
n
retinamid
figur
tabl
block
interact
high
nanomolar
affin
zikv
host
cell
importin
heterodim
wang
et
al
figur
inhibitor
hepat
c
viru
polymeras
olsen
et
al
could
inhibit
zikv
strain
cpe
reduct
assay
viru
yield
reduct
assay
vero
cell
african
green
monkey
kidney
cell
ecacc
tabl
zmurko
et
al
vivo
also
reduc
viremia
day
post
infect
delay
virusinduc
morbid
mortal
receptor
knockout
mice
infect
zikv
zmurko
et
al
sofosbuvir
figur
fdaapprov
nucleotid
polymeras
inhibitor
effici
inhibit
replic
infect
sever
zikv
strain
includ
african
american
isol
valu
jar
human
placent
choriocarcinoma
cell
tabl
bullardfeibelman
et
al
addit
oral
treatment
sofosbuvir
also
protect
zikvinduc
death
mice
li
z
et
al
use
virtual
screen
stephen
et
al
identifi
four
topscor
ligand
compound
includ
zikv
valu
respect
plaqu
reduct
assay
pra
tabl
figur
stephen
et
al
compound
may
cooper
interact
hydrophob
bind
pocket
extend
sadenosyl
homocystein
sah
bind
pocket
stephen
et
al
base
model
catalyt
domain
zikv
rnadepend
rna
polymeras
rdrpc
ligand
n
acetamid
chosen
potenti
inhibitori
activ
zikv
rdrpc
protein
act
gtpnucleotid
analog
prevent
initi
zikv
rna
polymer
figur
tabl
singh
jana
ribonucleotid
analog
like
inhibit
zikv
replic
figur
tabl
respect
measur
presenc
compet
utp
altern
nonradioact
coupledenzym
assay
lu
et
al
one
major
inhibitori
mechan
ribonucleotid
zikv
infect
direct
termin
viral
rna
polymeras
lu
et
al
merimepodib
mmpd
figur
potent
inhibitor
dehydrogenas
impdh
inhibit
zikv
rna
replic
cell
cytotox
assay
determin
result
select
index
tabl
tong
et
al
agonist
resiquimod
tolllik
receptor
tlr
agonist
inhibit
zikv
rna
synthesi
transform
microgli
celllin
figur
tabl
vanwalscappel
et
al
avc
figur
interferonactiv
agonist
trif
pathway
inhibit
replic
zikv
activ
innat
interferonassoci
respons
valu
well
dosag
observ
induc
detect
cytotox
thf
cell
tabl
pryke
et
al
along
selenium
freeform
amino
acid
sequenc
ffaap
compris
glycin
cystin
glutam
sourc
inhibit
zikv
replic
effect
dose
dose
zika
viru
inhibit
mm
human
cell
mm
vero
cell
tabl
vasireddi
et
al
histon
methyltransferas
suppress
gene
transcript
via
propag
repress
chromatin
domain
margueron
reinberg
di
croce
helin
kim
et
al
figur
inhibitor
histon
methyltransferas
verma
et
al
suppress
dna
virus
like
herp
simplex
viru
hsv
human
cytomegaloviru
adenoviru
infect
also
rna
viru
like
zikv
replic
human
foreskin
fibroblast
hff
cell
tabl
arbuckl
et
al
howev
report
favipiravir
figur
broadspectrum
antivir
effect
mani
virus
structur
analog
inhibit
zikv
strain
respect
vero
cell
tabl
cai
et
al
emricasan
figur
pancaspas
inhibitor
inhibit
zikvinduc
increas
activ
valu
cell
three
zikv
strain
cambodian
strain
ugandan
strain
puerto
rican
strain
tabl
xu
et
al
addit
assay
emricasan
also
reduc
total
number
activ
cleav
forebrainspecif
hnpc
human
cortic
neural
progenitor
cell
monolay
organoid
cultur
infect
zikv
strain
xu
et
al
two
halogen
chrysin
figur
inhibit
zikv
infect
cell
respect
suroengrit
et
al
cellbas
system
respect
tabl
suroengrit
et
al
investig
mechan
two
halogen
chrysin
action
suggest
multipl
target
maxim
effici
achiev
earli
postinfect
treatment
suroengrit
et
al
compound
confirm
inhibitor
zikvinduc
cytopath
effect
cpe
human
fetal
neural
stem
cell
nsc
figur
tabl
bernatchez
et
al
pki
pki
figur
pka
inhibitor
could
act
potent
inhibitor
asianamerican
african
lineag
zikv
replic
endotheli
cell
astrocyt
minim
cytotox
tabl
cheng
et
al
cavinafungin
figur
target
er
signal
peptidas
bind
inhibit
zikv
replic
nm
nm
cell
tabl
estoppey
et
al
manidipin
cilnidipin
voltageg
channel
vgcc
inhibitor
could
inhibit
zikv
infect
plaqu
format
observ
concentr
vero
cell
wang
et
al
accord
accumul
data
benidipin
hydrochlorid
pimecrolimu
nelfinavir
mesyl
also
inhibit
zikv
replic
concentr
vero
cell
tabl
figur
wang
et
al
five
deriv
nucleosid
analog
nucleosid
methyl
moieti
posit
ribos
ring
includ
figur
reduc
viral
titer
vero
cell
tabl
eyer
et
al
nucleosid
analog
show
weak
cytotox
effect
concentr
cell
prolifer
eyer
et
al
figur
aminobenzamidesulfonamid
compound
target
oligosaccharyltransferas
ost
isoform
block
viral
rna
replic
significantli
inhibit
viral
particl
format
cell
tabl
puschnik
et
al
nordihydroguaiaret
ndga
methyl
deriv
tetraomethyl
nordihydroguaiaret
acid
disturb
lipid
metabol
sterol
regulatori
elementbind
protein
srebp
figur
therebi
inhibit
zikv
isol
patient
si
si
respect
tabl
merinoramo
et
al
obatoclax
saliph
gemcitabin
affect
zikvmedi
transcript
figur
tabl
translat
posttransl
modif
well
metabol
pathway
differ
mechan
action
inhibit
zikv
infect
noncytotox
concentr
kuivanen
et
al
zmp
complex
protein
interferoninduc
transmembran
protein
ifitm
famili
coimmunoprecipit
studi
inhibit
zikv
viral
titer
cell
tabl
fu
et
al
figur
investig
compound
function
cdki
inhibit
three
zikv
stain
valu
measur
intracellular
zikv
rna
level
cell
tabl
xu
et
al
develop
antizikv
drug
requir
effect
strategi
exampl
use
exist
drug
librari
screen
drug
molecul
inhibit
new
target
effect
method
develop
new
drug
yang
et
al
kumar
et
al
siliconbas
drug
model
anoth
econom
use
strategi
identifi
candid
drug
short
amount
time
pal
et
al
kumar
et
al
addit
virtual
screen
electron
pharmacokinet
model
also
facilit
discoveri
effect
drug
molecul
rohini
et
al
first
virtual
screen
method
base
electron
pharmacodynam
adopt
screen
effect
inhibitor
zikv
protein
asin
databas
includ
molecul
rohini
et
al
complex
known
protein
inhibitor
use
establish
fivefeatur
pharmacophor
hypothesi
addrr
consist
one
hydrogen
bond
acceptor
two
hydrogen
bond
donor
two
aromat
ring
r
rohini
et
al
pharmacophor
model
verifi
enrich
analysi
virtual
screen
process
rohini
et
al
activ
develop
screen
method
assess
antivir
activ
compound
key
step
discoveri
new
drug
ekin
et
al
viru
replic
reli
cellular
mechan
mean
vitro
experi
use
host
cell
cultur
viru
replic
sinc
zikv
infect
mani
differ
cell
multipl
cell
line
use
studi
zikv
infect
screen
effect
drug
use
multipl
cell
provid
good
framework
drug
discoveri
barr
et
al
strategi
includ
rna
interfer
long
noncod
rna
mirna
interf
peptid
compound
target
viral
rna
han
mespled
underexplor
build
block
element
introduc
medicin
chemistri
nitsch
et
al
arthropodborn
singlestrand
posit
rna
viru
zikv
util
number
host
viral
protein
cellular
compon
accomplish
replic
cycl
includ
step
viral
entri
genom
replic
structur
nonstructur
protein
process
assembl
bud
virion
action
result
seri
congenit
abnorm
like
syndrom
adult
microcephali
newborn
fetal
demis
pregnanc
dick
et
al
viral
host
protein
involv
viru
life
cycl
serv
target
develop
smallmolecul
zikv
inhibitor
exampl
zikv
e
protein
respons
bind
viru
host
cell
receptor
mediat
viral
entri
host
cell
therefor
small
molecul
inhibitor
target
zikv
e
protein
effect
inhibit
viru
attach
entri
byrd
et
al
fernando
et
al
oo
et
al
axl
express
human
glial
cell
permit
zikv
bind
entri
host
glial
cell
nowakowski
et
al
meerten
et
al
small
molecul
compound
target
axl
may
effect
inhibit
zikv
infect
rausch
et
al
howev
compound
target
host
protein
may
affect
normal
function
caus
advers
effect
studi
shown
sinc
stem
region
zikv
e
protein
high
sequenc
similar
flaviviru
denv
yellow
fever
viru
yfv
zikv
inhibitor
target
region
also
highli
effect
denv
yfv
infect
yu
et
al
therefor
essenti
develop
small
molecul
compound
broad
flaviviru
inhibitori
activ
anoth
import
strategi
develop
small
molecul
zikv
inhibitor
target
differ
step
zikv
replic
cycl
synergist
antivir
effect
use
combin
numer
case
zikv
sexual
transmiss
report
recent
zikv
outbreak
studi
shown
zikv
also
replic
human
prostat
cell
spencer
et
al
howev
littl
known
viral
protein
host
factor
involv
event
therefor
essenti
identifi
protein
target
develop
smallmolecular
inhibitor
prevent
sexual
transmiss
zikv
increas
understand
viral
protein
structur
tremend
progress
made
structurebas
discoveri
inhibitor
target
structur
nonstructur
protein
zikv
e
protein
three
proteinas
construct
helicas
methyltransferas
polymeras
sever
seri
smallmolecul
zikv
inhibitor
target
protein
report
howev
test
vitro
small
percentag
compound
evalu
anim
model
vivo
advanc
clinic
trial
therefor
studi
focu
exploit
novel
strategi
identifi
new
antizikv
compound
elucid
mechan
action
improv
efficaci
antizikv
compound
evalu
vivo
efficaci
safeti
compound
suitabl
anim
model
patient
develop
smallmolecul
zikv
inhibitor
higheffici
low
toxic
bring
promis
clinic
treatment
zikv
infect
relat
diseas
near
futur
lw
rl
yg
yl
xd
rx
yz
fy
draft
manuscript
ty
sj
fy
revis
edit
manuscript
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
